Last reviewed · How we verify
NCT01562600
Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation
trial in Gastric Ulcer in 1,634 participants. Completed in 27 August 2015.
27 August 2015
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,634 |
| Start date | 19 April 2012 |
| Primary completion | 27 August 2015 |
| Estimated completion | 27 August 2015 |
| Sites | 46 locations across Japan |
Conditions studied
- Gastric Ulcer — all drugs for Gastric Ulcer →
- Duodenal Ulcer — all drugs for Duodenal Ulcer →
Sponsor
AstraZeneca — full company profile →
Who can join
Eligibility, any sex, with Gastric Ulcer or Duodenal Ulcer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with non-steroidal anti-inflammatory drug (NSAID).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01562600
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Ulcer
Currently open trials in the same condition.
- NCT07385235 — Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' · Phase 1 · recruiting
- NCT07032961 — A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening · recruiting
- NCT06848400 — Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios · NA · recruiting
- NCT06822413 — Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis · recruiting
- NCT03972956 — Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01562600 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 7 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01562600.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing